Beam Therapeutics Stock In The News
| BEAM Stock | USD 24.38 0.56 2.35% |
The overall news coverage of Beam Therapeutics from major news outlets shows bullish sentiment on 8 news articles, blog posts, and TV commentaries analyzed in the last few months. Our overall analysis of Beam Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Beam Therapeutics. The specific impact of Beam Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Beam Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Beam Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Beam Therapeutics Backtesting and Beam Therapeutics Hype Analysis. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.
Beam |
Beam Therapeutics Today Top News and Investor Outlook
Beam Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Beam and other traded companies coverage. We help investors stay connected with Beam headlines for the 4th of June to make an informed investment decision based on correlating the impacts of news items on Beam Stock performance. Please note that trading solely based on the Beam Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.Beam Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Beam earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Beam Therapeutics that are available to investors today. That information is available publicly through Beam media outlets and privately through word of mouth or via Beam internal channels. However, regardless of the origin, that massive amount of Beam data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Beam Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Beam Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Beam Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Beam Therapeutics alpha.
Beam Largest EPS Surprises
Earnings surprises can significantly impact Beam Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-11-10 | 2020-09-30 | -0.56 | -0.69 | -0.13 | 23 | ||
2023-11-08 | 2023-09-30 | -1.36 | -1.22 | 0.14 | 10 | ||
2020-08-12 | 2020-06-30 | -0.53 | -0.69 | -0.16 | 30 | ||
2024-05-07 | 2024-03-31 | -1.42 | -1.21 | 0.21 | 14 | ||
2022-11-07 | 2022-09-30 | -1.31 | -1.56 | -0.25 | 19 | ||
2022-05-09 | 2022-03-31 | -1.32 | -1.01 | 0.31 | 23 |
Beam Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Beam Therapeutics Stock. The global stock market is bullish. About 60% of major world exchanges and indexes are currently up. See today's market update for more information.
30th of May 2024
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference at benzinga.com
23rd of May 2024
Acquisition by Walsh Kathleen E of 16532 shares of Beam TherapeuticsInc at 34.33 subject t... at MacroaxisInsider
20th of May 2024
Acquisition by Walsh Kathleen E of 16532 shares of Beam TherapeuticsInc at 34.33 subject t... at news.google.com
16th of May 2024
DESERT MOUNTAIN ENERGY ANNOUNCES STRATEGIC PARTNERSHIP WITH BEAM EARTH LTD. FOR HYDROGEN I... at prnewswire.com
14th of May 2024
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 a... at finance.yahoo.com
13th of May 2024
Acquisition by Walsh Kathleen E of 16532 shares of Beam TherapeuticsInc at 34.33 subject t... at simplywall.st
10th of May 2024
Acquisition by Walsh Kathleen E of 16532 shares of Beam TherapeuticsInc at 34.33 subject t... at MacroaxisInsider
9th of May 2024
Acquisition by Walsh Kathleen E of 16532 shares of Beam TherapeuticsInc at 34.33 subject t... at MacroaxisInsider
2nd of May 2024
Ultragenyx Reports Q1 Loss, Lags Revenue Estimates at zacks.com
16th of April 2024
Acquisition by Walsh Kathleen E of 16532 shares of Beam TherapeuticsInc at 34.33 subject t... at news.google.com
3rd of April 2024
Beam Therapeutics CEO sells over 580k in company stock at investing.com
Beam Therapeutics Investors Sentiment
The influence of Beam Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Beam. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Beam Therapeutics' public news can be used to forecast risks associated with an investment in Beam. The trend in average sentiment can be used to explain how an investor holding Beam can time the market purely based on public headlines and social activities around Beam Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Beam Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Beam Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Beam Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Beam Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Beam Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Beam Therapeutics' short interest history, or implied volatility extrapolated from Beam Therapeutics options trading.
Additional Information and Resources on Investing in Beam Stock
When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports:Check out Beam Therapeutics Backtesting and Beam Therapeutics Hype Analysis. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 4.539 | Quarterly Revenue Growth (0.69) | Return On Assets (0.08) | Return On Equity (0.16) |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.